Evidence map›Paper›PMID 20920428›Full record

ArticleJournal of diabetes science and technology2010

Use of subcutaneous interstitial fluid glucose to estimate blood glucose: revisiting delay and sensor offset.

Kerstin Rebrin, Norman F Sheppard, Garry M Steil

Registry-linked trialAbstract readEvaluation Study
In one paragraph

Article in Journal of diabetes science and technology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03842683 (Are Todays Continuous Glucose Monitoring Precise and Can They be Used to Reveal and Reduce Glycaemic Variability?), which is not on this map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03842683 completednot on this mapstarted 2016, after this paper: background citation

Are Todays Continuous Glucose Monitoring Precise and Can They be Used to Reveal and Reduce Glycaemic Variability?

TypeobservationalSponsorPeter VestergaardRan2016 to 2017Enrolled472ConditionsDiabetes Type 1ArmsCGM
3 · Its place in the literature

Who cites it

78 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Value of continuous glucose monitoring for minimizing severe hypoglycemia during tight glycemic control.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2011
    Trial
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kerstin RebrinMicroCHIPS, Inc., Bedford, Massachusetts, USA.
Norman F Sheppard
Garry M Steil

Funding

SPECS: Safe Pediatric Euglycemia in Cardiac SurgeryR01HL088448 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI AGUS, MICHAEL SD · 2007 to 2011
$4.0M
NHLBI NIH HHS R01HL88448
6 · The paper itself

Abstract

backgroundEstimates for delays in the interstitial fluid (ISF) glucose response to changes in blood glucose (BG) differ substantially among research groups. We review these findings along with arguments that continuous glucose monitoring (CGM) devices used to measure ISF delay contribute to the variability. We consider the impact of the ISF delay and review approaches to correct for it, including strategies pursued by the manufacturers of these devices. The focus on how the manufacturers have approached the problem is motivated by the observation that clinicians and researchers are often unaware of how the existing CGM devices process the ISF glucose signal.

methodsNumerous models and simulations were used to illustrate problems related to measurement and correction of ISF glucose delay.

resultsWe find that (1) there is no evidence that the true physiologic ISF glucose delay is longer than 5-10 min and that the values longer than this can be explained by delays in CGM filtering routines; (2) the primary impact of the true ISF delay is on sensor calibration algorithms, making it difficult to estimate calibration factors and offset (OS) currents; (3) inaccurate estimates of the sensor OS current result in overestimation of sensor glucose at low values, making it difficult to detect hypoglycemia; (4) many device companies introduce nonlinear components into their filters, which can be expected to confound attempts by investigators to reconstruct BG using linear deconvolution; and (5) algorithms advocated by academic groups are seldom compared to algorithms pursued by industry, making it difficult to ascertain their value.

conclusionsThe absence of any direct comparisons between existing and new algorithms for correcting ISF delay and sensor OS current is, in part, due to the difficulty in extracting relevant details from industry patents and/or extracting unfiltered sensor signals from industry products. The model simulation environment, where all aspects of the signal can be derived, may be more appropriate for developing new filtering and calibration strategies. Nevertheless, clinicians, academic researchers, and the industry would benefit from collaborating when evaluating those strategies.

Indexed as

AlgorithmsAnimalsBiosensing TechniquesBlood GlucoseCalibrationExtracellular FluidFeasibility StudiesGlucoseHumansModels, BiologicalMonitoring, PhysiologicSignal Processing, Computer-AssistedTime FactorsUnited StatesUnited States Food and Drug AdministrationBlood GlucoseGlucose

Identifiers

PMID20920428
PMCPMC2956819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.